Ginkgo Bioworks, a biotech company from the United States, agreed to acquire FGen, a Swiss company specializing in strain development and optimization. Financial terms were not disclosed. "Our team has spent the last decade building one of the most advanced screening platforms in the world in the hopes of enabling breakthrough discoveries and products across industries. We are excited to be welcomed onto the Ginkgo platform where we can deploy this technology much more broadly and better support customers and their world-changing work," Andreas Meyer, FGen CEO.